121 related articles for article (PubMed ID: 38091978)
1. NGAL Mediates Anaplastic Thyroid Carcinoma Cells Survival Through FAS/CD95 Inhibition.
Crescenzi E; Mellone S; Gragnano G; Iaccarino A; Leonardi A; Pacifico F
Endocrinology; 2023 Dec; 165(2):. PubMed ID: 38091978
[TBL] [Abstract][Full Text] [Related]
2. NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells.
Volpe V; Raia Z; Sanguigno L; Somma D; Mastrovito P; Moscato F; Mellone S; Leonardi A; Pacifico F
J Clin Endocrinol Metab; 2013 Jan; 98(1):228-35. PubMed ID: 23150684
[TBL] [Abstract][Full Text] [Related]
3. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells.
Iannetti A; Pacifico F; Acquaviva R; Lavorgna A; Crescenzi E; Vascotto C; Tell G; Salzano AM; Scaloni A; Vuttariello E; Chiappetta G; Formisano S; Leonardi A
Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14058-63. PubMed ID: 18768801
[TBL] [Abstract][Full Text] [Related]
4. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil gelatinase-associated lipocalin protects renal tubular epithelial cells in hypoxia-reperfusion by reducing apoptosis.
Zang X; Zheng F; Hong HJ; Jiang Y; Song Y; Xia Y
Int Urol Nephrol; 2014 Aug; 46(8):1673-9. PubMed ID: 24973203
[TBL] [Abstract][Full Text] [Related]
6. NGAL promotes recruitment of tumor infiltrating leukocytes.
Pacifico F; Pisa L; Mellone S; Cillo M; Lepore A; Leonardi A
Oncotarget; 2018 Jul; 9(56):30761-30772. PubMed ID: 30112105
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein.
Borregaard N; Cowland JB
Biometals; 2006 Apr; 19(2):211-5. PubMed ID: 16718606
[TBL] [Abstract][Full Text] [Related]
8. Resistance to Fas-Mediated Apoptosis Does Not Correlate to Structural Alterations or Expression Changes of the Death Receptor in Papillary Thyroid Carcinomas.
; Saetta AA; Lazaris AC; Miaouli M; Voutsinas GE; Patsouris E; Tseleni-Balafouta S
Pathobiology; 2018; 85(5-6):304-310. PubMed ID: 30278467
[TBL] [Abstract][Full Text] [Related]
9. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.
Müller M; Wilder S; Bannasch D; Israeli D; Lehlbach K; Li-Weber M; Friedman SL; Galle PR; Stremmel W; Oren M; Krammer PH
J Exp Med; 1998 Dec; 188(11):2033-45. PubMed ID: 9841917
[TBL] [Abstract][Full Text] [Related]
10. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of cells with combined apoptosis and proliferation markers in thyroid tissue specimens from patients with cancer, adenoma, and autoimmune diseases.
Kazakov SP; Zabotina TN; Korotkova OV; Dzabarov AK; Kazantseva IA
Bull Exp Biol Med; 2011 Feb; 150(4):453-8. PubMed ID: 22268042
[TBL] [Abstract][Full Text] [Related]
12. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA; Kang KS; Di Cristofano A
Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia.
Schmidt-Ott KM; Mori K; Kalandadze A; Li JY; Paragas N; Nicholas T; Devarajan P; Barasch J
Curr Opin Nephrol Hypertens; 2006 Jul; 15(4):442-9. PubMed ID: 16775460
[TBL] [Abstract][Full Text] [Related]
14. Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.
Garg M; Kanojia D; Okamoto R; Jain S; Madan V; Chien W; Sampath A; Ding LW; Xuan M; Said JW; Doan NB; Liu LZ; Yang H; Gery S; Braunstein GD; Koeffler HP
J Clin Endocrinol Metab; 2014 Jan; 99(1):E62-72. PubMed ID: 24170107
[TBL] [Abstract][Full Text] [Related]
15. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
16. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
17. Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer.
Liu L; Li D; Chen Z; Yang J; Ma Y; Cai H; Shan C; Lv Z; Zhang X
Cell Physiol Biochem; 2017; 43(3):905-914. PubMed ID: 28957796
[TBL] [Abstract][Full Text] [Related]
18. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
[TBL] [Abstract][Full Text] [Related]
19. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury.
Mori K; Lee HT; Rapoport D; Drexler IR; Foster K; Yang J; Schmidt-Ott KM; Chen X; Li JY; Weiss S; Mishra J; Cheema FH; Markowitz G; Suganami T; Sawai K; Mukoyama M; Kunis C; D'Agati V; Devarajan P; Barasch J
J Clin Invest; 2005 Mar; 115(3):610-21. PubMed ID: 15711640
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
